SCHEMBL20630516

SCHEMBL20630516

N[C@@H](Cc1ccc(-n2cccn2)cc1)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 3/20 0.54
PTGS1 P23219 2/20 0.54
ALPI P09923 1/20 0.54
PKM P14618 1/20 0.54
XIAP P98170 1/20 0.54
TPH1 P17752 2/20 0.53
LMNA P02545 1/20 0.47
HSD17B10 Q99714 2/20 0.47
KDM4E B2RXH2 2/20 0.45
ALDH1A1 P00352 1/20 0.45
MAPK1 P28482 1/20 0.45
NOTUM Q6P988 1/20 0.45
DRD2 P14416 1/20 0.45
DRD4 P21917 1/20 0.45
DRD3 P35462 1/20 0.45
TYR P14679 5/20 0.44
GRB2 P62993 1/20 0.44
USP2 O75604 1/20 0.44
EGFR P00533 1/20 0.44
LCK P06239 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20630517 1.00 SLC7A5 (0.54) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL15648532 0.87 KDM4E (0.49) TPH1LMNAHSD17B10KDM4EALDH1A1
SCHEMBL6575361 0.84 MAPT (0.44) TPH1LMNAKDM4EALDH1A1MAPK1
SCHEMBL6575357 0.84 MAPT (0.44) TPH1LMNAKDM4EALDH1A1MAPK1
Hydrochloric Acid SCHEMBL6574263 0.83 MAPT (0.43) TPH1LMNAKDM4EALDH1A1MAPK1
SCHEMBL27951119 0.80 SLC7A5 (0.56) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL17768403 0.80 SLC7A5 (0.56) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL17817914 0.80 SLC7A5 (0.55) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL7256083 0.80 CAPN1 (0.46) PKMLMNAKDM4EALDH1A1MAPK1
SCHEMBL11829534 0.79 LMNA (0.46) LMNAKDM4EALDH1A1MAPK1NOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4724457-A2 RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF Rayzebio, Inc. (US) 2026-04-15 EP disclosed
EP-3650464-B1 PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND SHANGPHARMA INNOVATION INC (US) 2025-11-05 EP disclosed
WO-2024254339-A9 RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF RAYZEBIO, INC. (US) 2025-10-16 WO disclosed
EP-4545553-A2 PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND ShangPharma Innovation Inc. (US) 2025-04-30 EP disclosed
WO-2024254339-A2 RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF RAYZEBIO, INC. (US) 2024-12-12 WO disclosed
US-11981753-B2 Peptide compound and application thereof, and composition containing peptide compound SHANGPHARMA INNOVATION INC. (US) 2024-05-14 US disclosed
US-11807660-B2 Peptide compound and application thereof, and composition containing peptide compound XDCEXPLORER (SHANGHAI) CO., LTD. (CN) 2023-11-07 US disclosed
US-11427615-B2 Peptide compound and application thereof, and composition containing peptide compound XDCEXPLORER (SHANGHAI) CO., LTD. (CN) 2022-08-30 US disclosed
US-20220242908-A1 PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND THE BRIGHAM AND WOMEN'S HOSPITAL, INC. 2022-08-04 US disclosed
US-20220213142-A1 PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND THE BRIGHAM AND WOMEN'S HOSPITAL, INC. 2022-07-07 US disclosed
US-20200172575-A1 PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND XDCEXPLORER (SHANGHAI) CO., LTD. (CN) 2020-06-04 US disclosed
US-20200172575-A1 PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND XDCEXPLORER (SHANGHAI) CO., LTD. (CN) 2020-06-04 US disclosed
EP-3650464-A1 PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND XDCExplorer (Shanghai) Co., Ltd. (CN) 2020-05-13 EP disclosed
EP-3650464-A1 PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND XDCExplorer (Shanghai) Co., Ltd. (CN) 2020-05-13 EP disclosed
WO-2019007383-A1 PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND 凯惠科技发展(上海)有限公司 2019-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11981753-B2 Peptide compound and application thereof, and composition containing peptide compound KISS1R, NPY1R, GLP1R SLC7A5 831/4885PTGS1 3653/4885ALPI 3576/4885
US-11427615-B2 Peptide compound and application thereof, and composition containing peptide compound KISS1R, VIP, NPY1R SLC7A5 400/4885PTGS1 3602/4885ALPI 2329/4885
US-20220213142-A1 PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND KISS1R, VIP, SSTR3 SLC7A5 557/4885PTGS1 4537/4885ALPI 1695/4885
US-11807660-B2 Peptide compound and application thereof, and composition containing peptide compound KISS1R, VIP, SSTR3 SLC7A5 557/4885PTGS1 4537/4885ALPI 1695/4885
US-20220242908-A1 PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND KISS1R, NPY1R, GLP1R SLC7A5 831/4885PTGS1 3653/4885ALPI 3576/4885
US-20200172575-A1 PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND KISS1R, VIP, NPY1R SLC7A5 400/4885PTGS1 3602/4885ALPI 2329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.